Clients & Partners

Your operational ally — built for real-world care

Client identities and trademarks are confidential and not displayed publicly. References can be shared under NDA

Partnerships you can audit. Outcomes you can feel.

We collaborate with leading organizations across life sciences and healthcare to deliver safe, human, audit-ready home services nationwide.

Reputation chips

Top-5 Global CRO

1

Top-20 Pharma

2

National Hospital Network

3

Fortune 500 Insurer

4

Leading University Research Group

Representative client categories. References available upon NDA.

Featured Engagements

GSK3511294 — NIMBLE · Severe Asthma · Phase 3
• Non-inferiority vs mepolizumab/benralizumab when switching to depemokimab Q26W (52 weeks) • Eosinophilic phenotype

D3250C00101 — BRISOTE (benralizumab) · Severe Eosinophilic Asthma · Phase 3b
• Add-on benralizumab 30 mg SC vs escalation to high-dose ICS/LABA in patients uncontrolled on medium dose • Parallel, multicenter

D5180C00047 — ARRIVAL (tezepelumab) · Severe Asthma · Phase 3b (open-label/parallel)
• Assess reduction of maintenance medication while maintaining asthma control/remission • Q4W visits, up to 72 weeks

D9180C00012 — MIRANDA (tozorakimab) · COPD with exacerbations · Phase 3
• SC efficacy/safety in symptomatic COPD with ≥2 moderate or ≥1 severe exacerbation(s) in the prior 12 months, on optimized inhaled therapy

1397-0014 — AIRTIVITY (BI 1291583) · Bronchiectasis · Phase 3
• BI 1291583 vs placebo, up to 76 weeks, evaluating exacerbations and safety • Randomized, double-blind

NCT04719832 — SWIFT-1 (depemokimab) · Severe Eosinophilic Asthma · Phase 3
• Twice-yearly depemokimab reduced exacerbations vs placebo + SOC (results replicated in SWIFT-2) • 52-week design

NCT04718103 — SWIFT-2 (depemokimab) · Severe Eosinophilic Asthma · Phase 3
• Consistent with SWIFT-1: significant exacerbation reduction in eosinophilic phenotype

ANCHOR-2 (depemokimab) · CRSwNP · Phase 3
• Findings aligned with ANCHOR-1; pooled analysis showed reductions from baseline vs placebo

NCT03347279 — NAVIGATOR (tezepelumab) · Severe Asthma (12–80 y) · Phase 3
• Pivotal, double-blind, placebo-controlled trial: efficacy/safety of tezepelumab as add-on

D3251C00014 — RESOLUTE (benralizumab) · COPD with frequent exacerbations · Phase 3
• Efficacy/safety in COPD with elevated eosinophils; European registration (CTIS/EudraCT), NCT04053634

NCT04191304 — NATRON (benralizumab) · Hypereosinophilic Syndrome (HES) · Phase 3
• Benralizumab vs placebo in HES; exacerbation and symptom-control endpoints

D3250R00101 — BEST (benralizumab RWE) · Severe Eosinophilic Asthma · Real-World
• Real-world evidence (Russia): PROs (quality of life, sleep, anxiety, work) and effectiveness

D3250R00102 — RWE HRQoL/Benralizumab · Severe Asthma · Real-World
• Real-world data beyond clinical effectiveness: HRQoL, sleep, depression/anxiety, productivity

AIRLEAF → (Phase 2 preceding AIRTIVITY) (BI 1291583) · Bronchiectasis · Phase 2
• Cathepsin-C inhibitor reduced exacerbations; foundation to progress to Phase 3 (AIRTIVITY)

ONC-HaD-ES-RCT — Chemotherapy at Home vs Hospital · Oncology
• RCT in Spain: higher satisfaction at home due to nursing availability and communication; comparable safety/efficacy.

NCT01875367 — Phase III Preference SC vs IV Trastuzumab · HER2+ Breast Cancer
• Phase III, open-label: preference for the subcutaneous route (an enabler of at-home in HaD models) vs IV; satisfaction and logistics endpoints.

CA224-127 — RELATIVITY-127 (SC nivolumab + relatlimab vs IV) · Melanoma · Phase III
• Phase III trial: subcutaneous formulation compared with IV; facilitates hybrid models and potential home extension with nursing.

Impact Band

Query/incident ack

24 h

Regional activation

0 days

on-time visits

> 0 %

GDPR data flows · Standardized SOPs

Industry Coverage

Hospitals & Clinics — Home nursing · Follow-ups · Education
Insurers & Networks — Home procedures · Wound care · Reports
Telemedicine — Blood draws · Vitals · In-home education
University Research — Home visits · Logistics · Data entry
Global CROs/Sponsors (on request) — Last-mile ops · IATA logistics · eSource · Data Entry

Testimonials

“Transparent KPIs, fast deployment, consistent quality across regions.”
Program Manager, Southern Europe

“Seamless with our SOPs; patient experience remained high.”
Clinical Ops Lead, Iberia

Evidence Vault

We maintain a private vault with de-identified case summaries, SOP maps, and KPI extracts. Share your NDA and we’ll provide tailored references aligned to your scope and geography.

Contact

Name

Apellidos

Phone number

Servicios

Postal code

City

Aceptacion

I have read and accept the Privacy Policy, Terms and Conditions.

Legal

Legal Notice
Privacy Policy
Terms & Conditions
General Terms of Sale
Cookie Policy

Clients & Partners

Your operational ally — built for real-world care

Client identities and trademarks are confidential and not displayed publicly. References can be shared under NDA

Partnerships you can audit. Outcomes you can feel.

We collaborate with leading organizations across life sciences and healthcare to deliver safe, human, audit-ready home services nationwide.

Reputation chips

Top-5 Global CRO

1

Top-20 Pharma

2

National Hospital Network

3

Fortune 500 Insurer

4

Leading University Research Group

Representative client categories. References available upon NDA.

Featured Engagements

D5180C00047 — ARRIVAL (tezepelumab) · Severe Asthma · Phase 3b (open-label/parallel)• Assess reduction of maintenance medication while maintaining asthma control/remission • Q4W visits, up to 72 weeks

D9180C00012 — MIRANDA (tozorakimab) · COPD with exacerbations · Phase 3• SC efficacy/safety in symptomatic COPD with ≥2 moderate or ≥1 severe exacerbation(s) in the prior 12 months, on optimized inhaled therapy

1397-0014 — AIRTIVITY (BI 1291583) · Bronchiectasis · Phase 3• BI 1291583 vs placebo, up to 76 weeks, evaluating exacerbations and safety • Randomized, double-blind

NCT04719832 — SWIFT-1 (depemokimab) · Severe Eosinophilic Asthma · Phase 3• Twice-yearly depemokimab reduced exacerbations vs placebo + SOC (results replicated in SWIFT-2) • 52-week design

NCT04718103 — SWIFT-2 (depemokimab) · Severe Eosinophilic Asthma · Phase 3• Consistent with SWIFT-1: significant exacerbation reduction in eosinophilic phenotype

ANCHOR-2 (depemokimab) · CRSwNP · Phase 3• Findings aligned with ANCHOR-1; pooled analysis showed reductions from baseline vs placebo

NCT03347279 — NAVIGATOR (tezepelumab) · Severe Asthma (12–80 y) · Phase 3• Pivotal, double-blind, placebo-controlled trial: efficacy/safety of tezepelumab as add-on

D3251C00014 — RESOLUTE (benralizumab) · COPD with frequent exacerbations · Phase 3• Efficacy/safety in COPD with elevated eosinophils; European registration (CTIS/EudraCT), NCT04053634

NCT04191304 — NATRON (benralizumab) · Hypereosinophilic Syndrome (HES) · Phase 3• Benralizumab vs placebo in HES; exacerbation and symptom-control endpoints

D3250R00101 — BEST (benralizumab RWE) · Severe Eosinophilic Asthma · Real-World• Real-world evidence (Russia): PROs (quality of life, sleep, anxiety, work) and effectiveness

D3250R00102 — RWE HRQoL/Benralizumab · Severe Asthma · Real-World• Real-world data beyond clinical effectiveness: HRQoL, sleep, depression/anxiety, productivity

AIRLEAF → (Phase 2 preceding AIRTIVITY) (BI 1291583) · Bronchiectasis · Phase 2• Cathepsin-C inhibitor reduced exacerbations; foundation to progress to Phase 3 (AIRTIVITY)

ONC-HaD-ES-RCT — Chemotherapy at Home vs Hospital · Oncology • RCT in Spain: higher satisfaction at home due to nursing availability and communication; comparable safety/efficacy.

NCT01875367 — Phase III Preference SC vs IV Trastuzumab · HER2+ Breast Cancer • Phase III, open-label: preference for the subcutaneous route (an enabler of at-home in HaD models) vs IV; satisfaction and logistics endpoints.

CA224-127 — RELATIVITY-127 (SC nivolumab + relatlimab vs IV) · Melanoma · Phase III • Phase III trial: subcutaneous formulation compared with IV; facilitates hybrid models and potential home extension with nursing.